| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702878 | American Journal of Ophthalmology | 2017 | 20 Pages |
Abstract
Medicare Part B reimbursement for ophthalmologists was primarily driven by use of anti-vascular endothelial growth factor (anti-VEGF) injections from 2012 to 2013. Of the total drug payments to ophthalmologists, biologic anti-VEGF agents ranibizumab and aflibercept accounted for 95% of all drug reimbursement. This is in contrast to other specialties, in which drug reimbursement represented only a small portion of Medicare reimbursement.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Everett Han, Shivani Baisiwala, Atul Jain, M. Kate Bundorf, Suzann Pershing,